INTRODUCTION: The utility of blood-based Alzheimer's disease (AD) biomarkers in predicting clinical trajectories remains uncertain. METHODS: We assessed the diagnostic and prognostic performance of p-tau181, p-tau217, GFAP, and NfL in a large memory-clinic cohort (n=3,645) with comprehensive baseline clinical evaluatio...
X. Zeng, N. Heaton, R. A. Deek et al.· medRxiv· 0 citations
Current biobanking guidelines require in-person blood collection and immediate processing for Alzheimer's disease (AD) biomarker assessment. We recently reported that the P100 blood collection tubes containing protease inhibitors improve protein biomarker stability over delayed centrifugation periods. However, whether...
Yron K. Lee, X. Zeng, M. Farinas et al.· medRxiv· 0 citations
These findings support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment and support further evaluation of age-contextualized plasma p-tau217 interpretation for prognosis and trial enrichment.
R. Shi, L. Choity, S. Brodman et al.· medRxiv· 0 citations
A double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use, and positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads).
G. Blazhenets, D. Soleimani-Meigooni, Konstantinos Chiotis et al.· Journal of the American Medi...· 5 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
